Drug-Induced Pulmonary Fibrosis: National Database Analysis
Author Information
Author(s): Butranova Olga I., Terekhina Elizaveta N., Zyryanov Sergey K., Gildeeva Geliia N., Abramova Anna A., Kustov Yury O., Asetskaya Irina L., Polivanov Vitaly A.
Primary Institution: Peoples’ Friendship University of Russia Named after Patrice Lumumba (RUDN University)
Hypothesis
The objective of our study was to reveal the structure of drugs involved in PF development.
Conclusion
The study demonstrated increased reporting on pulmonary fibrosis in the National Pharmacovigilance database from 2019 to 2024, highlighting the significant role of antineoplastic and immunomodulating agents.
Supporting Evidence
- A total of 1308 spontaneous reports on pulmonary fibrosis were identified.
- 30.7% of patients with pulmonary fibrosis reported death.
- 51.9% of the drugs involved in pulmonary fibrosis were antineoplastic and immunomodulating agents.
Takeaway
This study looked at how certain drugs can cause lung problems called pulmonary fibrosis, and found that many cases are linked to cancer treatments.
Methodology
A retrospective descriptive pharmacoepidemiologic study on spontaneous reports with data on pulmonary fibrosis registered in the Russian National Pharmacovigilance database.
Limitations
The retrospective analysis does not allow for calculating the incidence of drug-induced pulmonary fibrosis related to specific pharmacologic groups.
Participant Demographics
Patients had a mean age of 59.3 years, with a majority being male (57.3%).
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website